Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Onconetix (ONCO) Payables (2023 - 2025)

Onconetix (ONCO) has disclosed Payables for 2 consecutive years, with $14.0 million as the latest value for Q3 2024.

  • On a quarterly basis, Payables rose 0.95% to $14.0 million in Q3 2024 year-over-year; TTM through Sep 2024 was $14.0 million, a 0.95% increase, with the full-year FY2023 number at $11.4 million, changed N/A from a year prior.
  • Payables was $14.0 million for Q3 2024 at Onconetix, up from $11.2 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $14.7 million in Q1 2024 to a low of $1.5 million in Q1 2023.